Mini Diamonds promoters pledge ₹8.88 cr for lab-grown pivot via warrants
Upendra and Ronish Shah will buy 1.11 cr convertible warrants at a 30% premium, funding the company's entry into lab-grown diamonds. The EGM is set for August 7.
— 3 earlier stories on Mini Diamonds (India) Ltd. →What's new
- Board approves 1.11 cr convertible warrants at ₹8 each, issuing to promoters Upendra and Ronish Shah
- Warrants priced at a 30% premium to market, aggregating ₹8.88 crore or ~6.2% of market cap
- Funds earmarked for lab-grown diamond expansion; EGM convened for August 7, 2026
Why this matters
For a nano-cap with a trailing net loss of ₹6 crore, a promoter-backed infusion at a premium signals conviction. The 4.5% dilution is manageable, but execution risk is real. The market now has specific terms for what was previously a vague board intimation.
What we're watching
- Shareholder approval at the August 7 EGM
- Initial revenue contribution from the lab-grown diamond business
- Any follow-on orders to complement the ₹16.25 cr and ₹14 cr orders from June 2026
The full read
Mini Diamonds' promoters are backing their lab-grown diamond pivot with their own capital. The board approved 1.11 crore convertible warrants at ₹8 each, raising ₹8.88 crore, about 6.2% of market cap. Upendra and Ronish Shah are paying a 30% premium to the market price. That is conviction. The funds will fuel expansion into lab-grown diamonds, which is growing faster than natural stones. But Mini Diamonds is coming off a ₹6 crore net loss in the March quarter on ₹150 crore revenue, so execution matters more than intent. The 4.5% dilution is manageable, and the EGM on August 7 is the next milestone. For a nano-cap with negative trailing profit, a promoter-backed infusion at a premium removes some funding uncertainty and aligns interests with minority holders. The lab-grown push is a significant opportunity, but the company has yet to prove it can turn potential into profit.
Questions answered
- What is the exact size and pricing of the preferential issue?
- Up to 1.11 crore convertible warrants at ₹8 each, aggregating ₹8.88 crore. Each warrant converts into one equity share of ₹2 face value within 18 months. The price is a 30% premium to the prevailing market price.
- Who are the allottees and why does the premium matter?
- The warrants are allotted to promoter group members Upendra Narottamdas Shah and Ronish U Shah. The 30% premium shows promoters are putting their own money where their strategy is, which is a strong signal for a company with recent losses.
- How much dilution does this cause?
- The issue represents about 6.2% of the current market cap and results in roughly 4.5% dilution. For a nano-cap, this exceeds the 2% materiality threshold, making it a significant event.
- What is the company's financial condition?
- Mini Diamonds has a market cap of ₹143 crore, but reported a net loss of ₹6 crore in the March 2026 quarter on sales of ₹150 crore. Trailing ROE is 5.3% and debt/equity is low at 0.04.
- What will the funds be used for?
- The proceeds will support the company's expansion into the lab-grown diamond business, marking a strategic pivot from natural diamonds.
- When is the shareholder approval expected?
- An extraordinary general meeting has been called for August 7, 2026, to seek shareholder approval for the preferential issue.
Mini Diamonds (India) Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on MINID →- 9 Jul 2026 · 11:15 AM IST Mini Diamonds promoters pledge ₹8.88 cr for lab-grown pivot via warrants
- 4d ago Mini Diamonds to mull preferential issue for lab-grown push
- 24d ago Mini Diamonds lands ₹16.25 cr order from Aura Diamond
- 25d ago Mini Diamonds lands ₹14 cr order from new Mumbai client